Type 1 Diabetes Clinical Trials in Seattle, Washington

6 studies are recruiting for type 1 diabetes in Seattle, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

   This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 393-days study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evalua…

   Stage

   Phase 1

   Ages

   12 to 35

   Site

   Benaroya Research Institute, Seattle, Washington

   Locations

   45 in total

   Run by

   COUR Pharmaceutical Development Company, Inc.

   See if you can join NCT06783309 on ClinicalTrials.gov

2. A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

   This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to <21 with recent-onset stage 3 T1D.

   Stage

   Phase 1

   Ages

   9 to 20

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   10 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT07061574 on ClinicalTrials.gov

3. SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

   This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).

   Stage

   Phase 2

   Ages

   5 to 40

   Site

   Benaroya Research Institute at Virginia Mason, Seattle, Washington

   Locations

   70 in total

   Run by

   SAb Biotherapeutics, Inc.

   See if you can join NCT07187531 on ClinicalTrials.gov

4. Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

   The primary objective of this study is to determine the effects of semaglutide on change in albuminuria from baseline to 26 weeks in type 1 diabetes. The secondary objective is to determine the effects of semaglutide on change in kidney parameters (including kidney oxygenation and function) measure…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Washington, Seattle, Washington

   Locations

   4 in total

   Run by

   University of Washington

   See if you can join NCT05822609 on ClinicalTrials.gov

5. InvesT1D: Promoting Adolescent Investment in Diabetes Care

   The goal of this clinical trial is to see if a financial incentives program called InvesT1D is helpful to support diabetes management in adolescents with type 1 diabetes. Adolescent participants will be randomized to usual care or receive financial incentives for meeting diabetes self-management an…

   Stage

   Not phased

   Ages

   12 and older

   Site

   Seattle Children's, Seattle, Washington

   Run by

   Harvard Pilgrim Health Care

   See if you can join NCT06384911 on ClinicalTrials.gov

6. MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

   Diabetic kidney disease and cardiovascular disease remain the leading causes of morbidity and mortality in people with type 1 diabetes and are exacerbated with longer duration of diabetes and time outside goal glycemic range. Yet, type 1 diabetes is a complex disease with pathophysiology that exten…

   Stage

   Phase 1

   Ages

   12 to 25

   Site

   Seattle Children's Hospital, Seattle, Washington

   Locations

   2 in total

   Run by

   Kalie Tommerdahl

   See if you can join NCT05065372 on ClinicalTrials.gov